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Secretoglobin and Transferrin Expression in Bronchoalveolar Lavage
Fluid of Horses with Chronic Respiratory Disease
M. Miskovic Feutz, L.L. Couetil, C.P. Riley, X. Zhang, J. Adamec, and R.E. Raskin
Background: Lower expression of secretoglobin and transferrin has been found in the bronchoalveolar lavage fluid
(BALF) of a small number of horses with experimentally induced signs of recurrent airway obstruction (RAO) compared to
healthy controls.
Hypothesis/Objectives: Secretoglobin and transferrin BALF expression will be similarly decreased in horses with naturally
occurring clinical signs of RAO and in horses with experimentally induced clinical signs of RAO as compared to healthy con-
trols and intermediate in horses with inflammatory airway disease (IAD).
Animals: Recurrent airway obstruction-affected and control horses were subjected to an experimental hay exposure trial
to induce signs of RAO. Client-owned horses with a presumptive diagnosis of RAO and controls from the same stable envi-
ronments were recruited.
Methods: Pulmonary function and BALF were evaluated from control and RAO-affected research horses during an
experimental hay exposure trial (n = 5 in each group) and from client-owned horses (RAO-affected horses, n = 17; IAD-af-
fected horses, n = 19; healthy controls, n = 5). The concentrations of secretoglobin and transferrin in BALF were assessed
using Western blots.
Results: Naturally occurring and experimentally induced RAO horses had similar decreases in BALF transferrin expres-
sion, but secretoglobin expression was most decreased in naturally occurring RAO. Secretoglobin and transferrin expression
were both lower in BALF of RAO-affected horses than in IAD-affected and control horses.
Conclusions and Clinical Importance: Secretoglobin and transferrin expression is decreased in BALF of RAO-affected
horses after both experimental and natural exposure. Secretoglobin and transferrin likely play clinically relevant roles in the
pathophysiology of RAO, and may thus be used as biomarkers of the disease.
Key words: Heaves; Inflammatory airway disease; Recurrent airway obstruction; Western blot.
Recurrent airway obstruction (RAO) is a chronicrespiratory disease in horses characterized by air-
way inflammation, obstruction, and hyperresponsive-
ness. Clinical signs of RAO include increased resting
respiratory effort, cough, and exercise intolerance.1
Recurrent airway obstruction has an environmental
allergy component as well as a genetic predisposition in
certain horses.1,2 Because of the wide genetic variation
among breeds and individual horses and the complex pathophysiology of allergic diseases, it has been difficult
to definitively elucidate the mechanisms of RAO.
Horses with IAD exhibit milder clinical signs including
coughing and poor performance with normal respira-
tory effort at rest.3
Pulmonary airways are the primary disease site in
RAO, and bronchoalveolar lavage fluid (BALF) has
been extensively studied in RAO-affected horses to
determine the pathophysiologic mechanisms that con-
tribute to RAO. Over 500 proteins have been identified
in BALF in healthy horses,4 and the use of traditional
methods for investigating changes in protein concentra-
tions in the face of disease exacerbation can be chal-
lenging because these techniques require preselection of
a very small number of potential mediators.
In a previous study utilizing proteomic techniques,
we identified 370 peptides corresponding to 250 unique
proteins in RAO-affected and control horses after an
experimental antigen exposure trial.5 Eighteen identified
peptides showed differential expression between the
RAO-affected and control horses. We validated the
expression levels of 2 proteins, secretoglobin and trans-
ferrin, using Western blots.
In this study, we used Western blots to evaluate
the expression levels of secretoglobin and transferrin
in a population of horses with naturally occurring
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clinical signs of RAO and environmentally matched
controls. Our primary hypothesis was that BALF
expression of secretoglobin and transferrin would be
similar in naturally occurring and experimentally
induced RAO and would be lower than in control
horses.
Materials and Methods
Animals
All procedures were approved by the Purdue University Ani-
mal Care and Use Committee. Five horses affected with RAO
(Purdue-owned RAO-affected) and 5 control horses (Purdue-
owned controls) were evaluated before and after experimental
exposure to moldy hay. The horses used in this study were the
same horses used in the exposure trial reported previously.5 In
the initial study,5 3 of the horses previously diagnosed with
RAO did not respond to the exposure trial. These horses were
excluded from the analysis for the study reported here. We
chose to include only the 5 control horses that were paired with
the RAO-affected horses (stalled adjacent and tested on the
same days) that had responded to the moldy hay challenge.
Forty-one horses were referred to the Purdue University College
of Veterinary Medicine after a mailed solicitation. Twenty cli-
ent-owned horses had a history of chronic respiratory disease
and were referred with a presumptive diagnosis of RAO. The
21 client-owned companion horses were from the same farms
and managed under the same conditions as the RAO-affected
horses, but had no history or clinical signs of respiratory dis-
eases. All horses were fed some type of hay during the year.
One horse that had been diagnosed previously with RAO was
fed hay cubes, 1 was fed haylage, and 1 was only fed hay dur-
ing the winter months. A variety of treatment options had been
pursued for the horses with a presumptive diagnosis of RAO.
None of these horses had been treated in the 2 weeks before
this study. Detailed treatment information was not available for
all horses. For all other horses, hay was fed both inside the
barn and outside at pasture. More than half the horses (22/41)
were fed hay from large round bales. Most horses were stabled
for at least part of the day throughout the year (15/41 were
stabled for more than 6 hours/d; 12/41 were never stabled).
Horses were bedded on straw, wood shavings, or sawdust
when they were stalled. All client-owned horses underwent the
same pulmonary function testing and BALF collection as the
Purdue-owned horses but were not subjected to a hay exposure
trial.
In order to be considered a control horse, the horse must
have had no history of chronic respiratory disease, no evidence
of airway obstruction (maximum change in transpulmonary
pressure [ΔPLmax] < 10 cm H2O) and <10% neutrophils, <1%
eosinophils, and <2% mast cells on BALF cytology. Horses
affected with RAO were diagnosed based on a history of
chronic respiratory disease (>3 months), increased respiratory
efforts upon presentation, evidence of airway obstruction
(ΔPLmax > 10 cm H2O), and >10% neutrophils on BALF cytol-
ogy. Inflammatory airway disease (IAD) was diagnosed based
on normal pulmonary function testing (ΔPLmax < 10 cm H2O)
and >10% neutrophils, >1% eosinophils, or >2% mast cells on
BALF cytology; history of client-reported respiratory disease
was variable. After testing, 17 horses were determined to have
RAO, 5 horses were healthy controls, and the remaining 19
horses had IAD. Some of the horses that were presented with a
presumptive diagnosis of RAO were actually diagnosed with
IAD. Similarly, many of the horses presented as healthy con-
trols were diagnosed with IAD.
Respiratory Evaluation
Testing was performed according to standard laboratory proce-
dures as previously described.6 A physical examination was
performed on each horse and a clinical score (range, 0–21) was
calculated based on respiratory rate and effort, thoracic ausculta-
tion findings, cough, and nasal discharge.7 The horses were then
restrained in stocks without sedation and fitted with an esophageal
balloon catheter, a face mask, and a pneumotachometer as
described previously.6 Breath-by-breath measurement of esopha-
geal and mask pressures and airflow were performed. Data analy-
sis of 10 representative breaths yielded mean total pulmonary
resistance, dynamic compliance, and ΔPLmax. After pulmonary
function testing, horses were sedated with butorphanol and deto-
midine in preparation for BAL. Bronchoalveolar lavage was
performed using a 2-m long video-endoscope and 250-mL bolus of
sterile saline solution as described previously.8 The BALF was
placed on ice and processed within 20 minutes of collection.
BALF Analysis
An aliquot of BALF was prepared for cytological examina-
tion by cytocentrifugation and stained with modified Wright’s
stain. Total nucleated cell counts were determined by use of a
hemacytometer. Differential cell counts were determined by the
examination of 200 leukocytes per slide. The clinical pathologist
evaluating the BALF cytology was blinded to each horse’s
group identity. The remainder of the BALF was filtered through
sterile gauze and centrifuged at 300 9 g for 10 minutes. Protein
concentration in the BALF of each horse was measured using a
BCA assay,a according to the manufacturer’s protocol. The
supernatant was stored at 80°C in 1 mL aliquots until further
analysis.
Western Blot
Secretoglobin and transferrin expression in BALF supernatant
was quantified by Western blot in the Purdue-owned RAO-affected
and control horses before and after the experimental exposure trial
(n = 5 in each group), client-owned RAO-affected horses with nat-
urally occurring disease (n = 17), client-owned healthy controls
(n = 5), and client-owned IAD-affected horses (n = 19). Western
blots were performed according to the manufacturer’s recommen-
dationsb to confirm the identity of secretoglobin and transferrin in
all BALF samples with 2 lg of protein from each sample. In the
Western blot for secretoglobin, the positive control protein was
equine recombinant secretoglobinc with monoclonal rabbit anti-
horse secretoglobin antiserum as the primary antibodyc (dilution
1 : 1000) and horseradish peroxidase-conjugated goat antirabbit
IgG as the secondary antibodyd (dilution 1 : 2000). In the Western
blot for transferrin, the positive control protein was human apo-
transferrine with polyclonal sheep antihorse transferrin as the
primary antibodyf (dilution 1 : 10,000) and horseradish peroxi-
dase-conjugated donkey antisheep IgG (H + L) as the secondary
antibodyg (dilution 1 : 100,000). ImageJ softwareh was used to
quantify the density of the bands from the protein of interest in
each Western blot.
Statistical Analysis
Statistical analysis was performed with Statistica.f,i A factorial
ANOVA was used to evaluate pulmonary function, BALF, and
Western blot data among the Purdue-owned horses before and
after the experimental exposure trial. The Fisher’s least significant
differences (LSD) test was used for posthoc testing.
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For the client-owned horses, the Mann–Whitney U-test was
used to perform pairwise comparisons evaluating pulmonary func-
tion, BALF, and Western blot data between RAO-affected and
control horses from the same environment (n = 4 in each group)
and between RAO-affected and IAD-affected horses from the same
environment (n = 12 in each group). The Kruskal–Wallis ANOVA
was used to evaluate differences among all 3 groups of horses
(RAO-affected n = 17, IAD-affected n = 19, control n = 5). The
multiple comparisons test was used for posthoc testing.
The Mann–Whitney U-test was used to compare pulmonary
function, BALF, and Western blot data between the Purdue-
owned control horses at baseline (n = 5) and the client-owned con-
trol horses (n = 5) and between the Purdue-owned RAO-affected
horses at exposure (n = 5) and the client-owned RAO-affected
horses (n = 17) to assess the validity of the experimental model as
a comparison population. The groups were found to be compara-
ble, and thus were pooled together for further analysis of the Wes-
tern blot data.
The relationship between the density of secretoglobin and trans-
ferrin expression in BALF and pulmonary function testing vari-
ables and BALF cytology variables was evaluated using the
Spearman rank correlation test. All available pulmonary function,
BALF, and Western blot data were used in this analysis (i.e., data
from all Purdue-owned and client-owned horses). In all statistical
analyses, P < .05 was considered statistically significant. Data are
presented as median (range).
Results
Respiratory Evaluation, Purdue-Owned Horses
The control horses were younger (16 years [10–19])
than the RAO-affected horses (21 years [17–26],
P = .012). There were no differences in the weights of
the horses. At baseline, there was no significant differ-
ence in the pulmonary function or BAL parameters
between RAO-affected and control horses. After expo-
sure, the RAO-affected horses had evidence of airway
obstruction and neutrophilic airway inflammation
(Table 1).
The control horses also had some differences between
baseline and exposure, namely an increase in the per-
centage of neutrophils in BALF and a decrease in the
percentage of lymphocytes in BALF at exposure. There
were no changes in the pulmonary function measure-
ments of the control horses between baseline and
exposure (Table 1).
Respiratory Evaluation, Client-Owned Horses
There was no significant difference in age or body
weight among the 3 groups of client-owned horses. The
RAO-affected horses showed evidence of airway
obstruction and had a higher clinical score than did the
control and IAD-affected horses (Table 2). The RAO-
affected horses had a decreased percentage of macro-
phages and an increased percentage of neutrophils in
BALF compared to the control and IAD-affected
horses. The IAD-affected horses had an increased per-
centage of eosinophils in BALF compared to the RAO-
affected horses.
The RAO-affected horses had a higher clinical score,
evidence of airway obstruction, and airway neutrophil-
ia. The IAD-affected horses had eosinophilic, mast cell,
or neutrophilic airway inflammation, but no detectable
airway obstruction (Table 3).
Comparison of Purdue-Owned to Client-Owned
Horses
We compared the Purdue-owned control horses at
baseline to the client-owned control horses and the
Purdue-owned RAO horses at exposure to the client-
owned RAO horses to assess the validity of using the
experimentally induced disease as a model for the nat-
urally occurring disease. We chose to use the Purdue-
owned horses at baseline because this location was
their natural environment. The exposure status of these
horses was after a moldy hay challenge. Although the
client-owned horses had been in an environment that
elicited clinical signs in RAO-affected horses after
long-term exposure, we did not feel that this environ-
ment was comparable to the moldy hay challenge that
Table 1. Summary statistics concerning Purdue-owned RAO and control horses before and after experimental expo-
sure to moldy hay. Data displayed as median (range).
Baseline Hay exposure
Controls (n = 5) RAO (n = 5) Controls (n = 5) RAO (n = 5)
Clinical score 1 (1–2) 2 (1–4) 3 (1–3) 11 (7–13)†,‡
ΔPmax (cm H2O) 6.2 (3.1–10.0) 5.1 (1.8–13.0) 5.9 (5.4–8.5) 26.6 (21.8–34.8)
†,‡
Cdyn (L/cm H2O) 3.7 (1.7–6.7) 4.7 (1.0–7.7) 3.4 (1.3–4.4) 0.6 (0.4–1.0)
‡
Rl (cm H2O/l/s) 0.4 (0.2–0.9) 0.4 (0.2–1.2) 0.5 (0.4–0.7) 1.8 (1.5–2.1)
†,‡
% BALF macrophages 62 (52–69) 48 (22–65) 55 (49–69) 32 (12–48)†
% BALF neutrophils 4 (3–4) 18 (3–53) 24 (18–31)* 49 (31–70)†,‡
% BALF lymphocytes 27 (22–40) 27 (10–43) 13 (10–19)* 11 (7–24)‡
% BALF eosinophils 0 (0–0) 0 (0–3) 0 (0–1) 0 (0–5)
% BALF mast cells 3 (0–5) 2 (1–6) 2 (0–6) 1 (0–6)
ΔPmax, maximum transpulmonary pressure change; Cdyn, lung dynamic compliance; Rl, lung resistance; BALF, bronchoalveolar lavage
fluid; AUC, area under the curve; RAO, recurrent airway obstruction.
†Significantly different from controls at exposure (P < .05).
‡Significantly different from RAO at baseline (P < .05).
*Significantly different from controls at baseline (P < .05).
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the Purdue-owned control horses experienced before
evaluation. The Purdue-owned RAO-affected horses
were older (21 years [17–26]) than the client-owned
RAO horses (15 years [8–21]; P = .0064). In the com-
parison between the 2 control groups (n = 5 in each
group), the client-owned horses had slightly higher res-
piratory rates (14 breaths/min [12–19]) than the Pur-
due-owned horses (9 breaths/min [6–11]; P = .021).
This difference was attributed to the familiarity of the
Purdue-owned horses with the laboratory environment.
Otherwise, there were no significant differences in pul-
monary function measurements or in the cell percent-
ages in BALF between the 2 groups. In addition, the
average clinical, functional, and cytological variables of
RAO horses were similar in magnitude, and data
ranges for Purdue-owned horses were within the data
ranges for client-owned horses.
Western Blots
In the Purdue-owned horses, the RAO-affected horses
at exposure had lower expression of transferrin than at
baseline (P < .001), and lower expression of transferrin
than the control horses at exposure (P = .0011; Fig 1).
The client-owned RAO-affected horses had lower
expression of transferrin than did the client-owned
IAD-affected horses (P = .030), but no significant differ-
ence was observed from the client-owned control horses
(Fig 2). The client-owned RAO-affected horses also had
a lower expression of secretoglobin than did the client-
owned IAD-affected horses (P < .001) and the client-
owned control horses (P = .0037; Figs 1 and 2). When
compared with the IAD-affected horses from the same
environments, the client-owned RAO-affected horses
had no difference in transferrin expression, but a lower
secretoglobin expression (P = .0014; Table 3).
When comparing the Purdue-owned horses to the cli-
ent-owned horses, we found no differences in transferrin
or secretoglobin expression in the control groups. The
Purdue-owned RAO-affected horses had higher secre-
toglobin expression than did the client-owned RAO-af-
fected horses (P = .017; Fig 1), but no difference in
transferrin expression.
The expression of secretoglobin and transferrin in
BALF were both negatively correlated with clinical
score, indicators of airway obstruction, and percentage
of neutrophils in the BALF (Table 4). The expression
of transferrin also was positively correlated with the
percentage of mast cells in BALF (Table 4).
Discussion
In this study, we evaluated 2 populations of RAO-af-
fected horses with environmentally matched pairs:
RAO-affected horses with clinical signs exacerbated by
Table 2. Summary statistics concerning client-owned
RAO, IAD and control horses. Data displayed as med-
ian (range).
Controls
(n = 5) RAO (n = 17) IAD (n = 19)
Clinical score 2 (0–5) 10 (4–17)‡ 4 (0–9)
ΔPmax (cm H2O) 5.4 (4.1–6.4) 16.3 (10.5–66.6)
‡ 6.4 (3.2–9.2)
Cdyn (l/cm H2O) 2.8 (0.7–6.9) 0.8 (0.2–7.6) 2.8 (1.4–7.5)
Rl (cm H2O/l/s) 0.4 (0.2–0.6) 1.5 (0.7–5.6)
‡ 0.4 (0.3–0.6)
% BALF
macrophages
59 (43–63) 19 (2–53)‡ 50 (11–77)
% BALF
neutrophils
4 (2–6) 44 (12–95)‡ 11 (1–60)
% BALF
lymphocytes
35 (29–50) 21 (2–70) 24 (9–55)
% BALF
eosinophils
0 (0–0) 0 (0–0)† 0 (0–4)
% BALF
mast cells
1 (0–2) 0 (0–4) 3.0 (0–9)
RAO, recurrent airway obstruction; IAD, inflammatory airway
disease; BALF, bronchoalveolar lavage fluid.
†Significantly different from IAD-affected horses (P < .05).
‡significantly different from controls and IAD-affected horses
(P < .05).
Table 3. Comparison of respiratory parameters between groups of client-owned horses originating from the same
stable environment (12 RAO/IAD pairs and 4 RAO/control pairs).
RAO
N = 12
IAD
N = 12
RAO
N = 4
Controls
N = 4
Clinical score 12 (6–17)* 3 (0–9) 8 (4–13)† 2 (0–5)
ΔPmax (cm H2O) 16.3 (11.3–66.6)* 6.7 (4.3–9.0) 22.5 (18.9–26.0) 6.0 (4.1–6.4)
Cdyn (L/cm H2O) 0.8 (0.4–7.6) 2.4 (1.5–3.9) 0.6 (0.2–0.9) 2.4 (0.7–3.17)
Rl (cm H2O/l/s) 1.2 (0.7–5.6)* 0.4 (0.3–0.6) 2.2 (1.4–3.1) 0.4 (0.2–0.6)
% BALF macrophages 31 (2–53)* 54 (11–73) 16 (13–23)* 57 (43–61)
% BALF neutrophils 44 (12–93)* 12 (2–48) 27 (5–53)† 4 (2–6)
% BALF lymphocytes 18 (2–60) 22 (9–46) 43 (24–70) 39 (31–50)
% BALF eosinophils 0.0 (0.0–0.0)* 0.3 (0.0–4.5) 0.0 (0.0–19.0) 0 (0–0)
% BALF mast cells 0 (0–3)* 3 (0–5) 3 (0–11) 1 (0–2)
Secretoglobin (relative density) 874 (299–4307)* 8181 (1210–10892) 696 (140–1120)* 6506 (5121–10146)
Transferrin (relative density) 4136 (167–7075) 5882 (2970–7720) 4223 (1142–5693) 7005 (1875–7342)
RAO, recurrent airway obstruction; IAD, inflammatory airway disease; BALF, bronchoalveolar lavage fluid.
*Parameter significantly different between the RAO horses and the other group of horses originating from the same stable environment
(P < .05).
†Trend toward a difference between the RAO horses and the other group of horses originating from the same stable environment
(P = .057).
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an experimental exposure to moldy hay and companion
control horses, and RAO-affected horses with clinical
signs exacerbated by natural environmental exposure
and companion control and IAD-affected horses. When
comparing the 2 groups of RAO-affected and control
horses, we found negligible differences between the vari-
ables assessed. Presumably, the types and amounts of
allergens to which the 2 groups of RAO-affected horses
were exposed and the length of exposure varied, how-
ever, the horses showed a similar degree of small airway
obstruction and pulmonary inflammation. With these
similarities, we can expect similar differences in the
protein composition of the BALF.
From the selection of peptides that showed differen-
tial expression between the RAO-affected and control
horses in a previous study,5 we chose to validate the
identity and expression levels of secretoglobin and
transferrin. Both proteins have been implicated in the
pathogenesis of respiratory diseases in humans,9–12 and
secretoglobin has been implicated in the pathogenesis of
RAO in horses.13,14 We were also able to obtain
equine-specific reagents for Western blots for both
proteins.
Secretoglobin expression was significantly decreased
in the RAO-affected horses compared to that in the
control horses and IAD-affected horses. This finding is
in agreement with previous studies evaluating secre-
toglobin in RAO.13 Our previous study showed no sig-
nificant difference in the experimental exposure model
between RAO-affected and control horses after both
groups of horses were subjected to the experimental
antigen exposure.5 We suspect this finding was a result
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Fig 1. Relative band density of Western blots performed using BALF samples probed with monoclonal antibodies against (A) Transferrin
and (B) Secretoglobin. Samples were collected from Purdue-owned (PU) control and RAO horses at baseline and after exposure to moldy
hay and from client-owned (Client) control, RAO, and IAD horses. BALF, bronchoalveolar lavage fluid; RAO, recurrent airway obstruc-
tion; IAD, inflammatory airway disease.
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of small sample size, relatively short duration of
antigenic exposure, and individual variation in secre-
toglobin concentrations. In addition, the control horses
in the experimental exposure model did show some
degree of airway inflammation after exposure to a dusty
environment. In this larger study, the lower concentra-
tions of secretoglobin in equine BALF in naturally
occurring RAO compared to control horses without
pulmonary inflammation strongly suggest that pro-
longed exposure to environmental antigens is associated
with depletion of secretoglobin as hypothesized by
others.13 An additional finding was that secretoglobin
expression was significantly higher in horses with IAD
compared to those with RAO. Horses with IAD may
be difficult to differentiate from those with RAO based
on clinical signs and BALF cytology alone. Pulmonary
function testing is considered the reference standard,
but is only available at few referral centers.6 Because of
the correlation between secretoglobin in BALF and
indicators of airway disease severity, this protein may
prove to be a valuable biomarker to help differentiate
mild (IAD) from severe (RAO) chronic airway disease.
Secretoglobin is an anti-inflammatory protein that
inactivates phospholipase A2, decreases proinflamma-
tory cytokine production, alters phagocyte function,
and may decrease the inflammatory response to endo-
toxin.11 The pathophysiologic mechanism of secre-
toglobin in RAO of horses and asthma of humans is
still unclear, but it does appear to play a role in both
diseases. Secretoglobin is decreased in the serum of
humans with asthma.9 Secretoglobin-positive airway
epithelial cells are fewer in number in people with
asthma and in horses with RAO.13,15 Based on the stud-
ies in secretoglobin-deficient mice, secretoglobin seems
to be necessary for adequate viral clearance and attenu-
ation of the pulmonary inflammatory response to viral
infection and allergen exposure.16,17
Although most mammals have only 1 gene that
encodes the secretoglobin protein, horses have 3 such
genes.18 One of these genes is thought to be a pseudo-
gene, whereas the other 2 code for functional, but dif-
ferent, secretoglobin proteins. Horses with RAO
showing clinical signs do have a different expression of
the 2 secretoglobin variants than do control horses, and
it seems to be associated with differential effects on neu-
trophil function.19 This relationship has not yet been
evaluated in horses with IAD. However, the difference
in BALF secretoglobin expression between RAO-af-
fected and IAD-affected horses implies that these
diseases may have different pathophysiology or repre-
sent variable severity of the same disease process.
The expression of transferrin in BALF was signifi-
cantly lower in RAO-affected horses compared to IAD-
affected horses and control horses. Because transferrin
is a negative acute phase protein, a decrease in the face
of inflammation is expected with both RAO and IAD.
The relationship between transferrin and pulmonary
inflammation is not as clear as that of secretoglobin. In
STD RAO1 RAO2 RAO3 RAO4 RAO5 RAO6 CTL1 CTL2 CTL3 CCSP BLK
TF2 TF1.5 TF1      BLK   CTL1    CTL2     CTL3   CTL4   CTL5    CTL6    RAO1   RAO2  RAO3  RAO4  RAO5
A
B
Fig 2. Western blots performed using BALF samples collected from client-owned control horses (CTL) and horses with recurrent airway
obstruction (RAO). (A) Secretoglobin, (B) Transferrin. BLK: blank; STD: protein standards. TF2: 2.0 lg of transferrin control protein
(human apo-transferrin). BALF, bronchoalveolar lavage fluid.
Table 4. Correlation coefficients (r) between secre-
toglobin and transferrin expression and various respira-
tory parameters (clinical score, pulmonary function,
BALF cytology) collected from horses with chronic res-
piratory disease and controls (n = 60).
Secretoglobin Transferrin
r P value r P value
Clinical score 0.57 <.001 0.48 <.001
ΔPmax (cm H2O) 0.50 <.001 0.62 <.001
Cdyn (l/cm H2O) 0.46 .0015 0.19 .20
Rl (cm H2O/l/s) 0.50 <.001 0.61 <.001
% BALF macrophages 0.51 <.001 0.41 .0010
% BALF neutrophils 0.33 .0093 0.36 .0051
% BALF lymphocytes 0.087 .51 0.025 .85
% BALF eosinophils 0.068 .61 0.083 .53
% BALF mast cells 0.033 .80 0.32 .014
BALF, bronchoalveolar lavage fluid.
Secretoglobin and Transferrin in RAO 1697
people with acute exposure to swine dust, BALF trans-
ferrin concentration actually increases within 24 hours
of exposure.12 This previous study hypothesized that
the acute increase in BALF transferrin is caused by
plasma exudation into the airways in the face of acute
inflammation. Patients with acute respiratory distress
and on a mechanical ventilator have lower BALF trans-
ferrin concentrations than do healthy controls, but
patients with chronic obstructive pulmonary disease and
on a mechanical ventilator have higher BALF transfer-
rin concentrations than do healthy controls.20 Patients
in status asthmaticus have higher sputum transferrin
concentrations than do patients with chronic bronchitis
(healthy control subjects were not evaluated in this
study).21 Serum and BALF transferrin concentrations
are higher in people with methylene diisocyanate-in-
duced occupational asthma, compared to asymptomatic
people exposed to the same environment (exposure of
4–5 years).22 Because transferrin is a predominant
plasma protein, it is likely that increases in BALF or
sputum transferrin concentrations reflect plasma exuda-
tion into the lungs, and it may be difficult to separate
pulmonary transferrin production from systemic
transferrin production without serial measurements of
transferrin concentration in both BALF and serum.
Another option to assess pulmonary transferrin produc-
tion, rather than performing serial measurements, could
be to correct for BALF dilution using inulin as an
exogenous marker or urea as an endogenous marker of
pulmonary epithelial lining fluid concentration in the
collected BALF.23
The timing of sample collection should be noted
when evaluating transferrin concentrations. The median
time that the Purdue-owned horses were under environ-
mental challenge was 4 days (range 3–7 days; testing
was performed on the first day of increased respiratory
efforts), whereas the client-owned horses displayed
clinical signs of RAO exacerbation in their home envi-
ronments for a median of 22 months (range,
3–129 months). The timing of transferrin measurement
reported in studies of humans has varied from 24 hours
to 5 years of environmental exposure.20,22 Transferrin
concentrations may change with the duration and sever-
ity of inflammation, and thus the discrepancy in results
between studies is not surprising.
Although we believe that RAO-affected horses are
suitable models for humans with severe asthma, care
must be used when extrapolating data between species.
Equine RAO is a naturally occurring disease that shares
the asthmatic characteristics of airway inflammation,
airway obstruction, and airway hypersensitivity. The
pulmonary anatomy of horses is very similar to that of
humans. The genetic characteristics of RAO are also
quite complex, as is the genetic background of the
horses with the disease.24
One limitation to RAO in horses as a model for
asthma in humans is the primary inflammatory cell
involved in the diseases. In RAO, the neutrophil is the
primary pulmonary inflammatory cell, whereas the eosi-
nophil is the major inflammatory cell in most forms of
mild allergic asthma. However, in severe acute asthma,
the neutrophil is more commonly associated with pul-
monary inflammation.25 Keeping in mind the cytologic
characteristics of the 2 diseases, RAO may serve as a
valuable model for severe acute asthma and IAD as a
model for mild asthma.
One unexpected finding from this study was the large
number of client-owned horses that were presented with
no history of respiratory disease that in fact had IAD.
In addition, some horses with a presumptive diagnosis
of RAO actually had IAD. Most of the client-owned
horses evaluated in this study were older and retired
from high-level activity, which could lead to undetected
clinical signs of IAD (because it typically is associated
with impaired athletic performance). This finding high-
lights the necessity of identifying biomarkers to differen-
tiate between RAO and IAD in the field, otherwise only
pulmonary function testing in conjunction with BALF
cytology allows that differentiation. In addition, it is
likely that the incidence of IAD in older horse popula-
tions is under-represented because of the lack of owner
complaints of respiratory signs.
This study demonstrated that RAO-affected horses
during exacerbation of clinical signs had lower secre-
toglobin and transferrin expression in their BALF than
did healthy control horses or horses with IAD. These
differences suggest that secretoglobin and transferrin
may be useful in the future as biomarkers or as possible
treatment targets for RAO.
Footnotes
a Thermo Scientific, Rockford, IL
b Invitrogen, Carlsbad, CA
c gift from Dr Dorothee Bienzle, Ontario Veterinary College,
University of Guelph, Guelph, ON, Canada
d Goat anti-rabbit HRP, catalog # AP307P; Chemicon Interna-
tional, Darmstadt, Germany
e Human apo-transferrin, catalog # 3188-AT; R&D Systems, Min-
neapolis, MN
f Sheep anti-horse transferrin, catalog # A70-110A; Bethyl Labora-
tories, Montgomery, TX
g Donkey anti-sheep IgG, catalog # 713-035-147; Jackson
Immunoresearch Laboratories, Inc, West Grove, Pennsylvania,
PA
h National Institutes of Health, Bethesda, MD
i StatSoft, Inc, Tulsa, OK
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